PFMU
LENZ

Privium Fund Management (UK)’s LENZ Therapeutics LENZ Stock Holding History

Privium Fund Management (UK)’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27,321
Closed -$453K – 92
2023
Q3 		$453K Sell
27,321
-10,230
-27% -$178K 0.35% 53
2023
Q2 		$694K Sell
37,551
-2,701
-7% -$54K 0.55% 45
2023
Q1 		$685K Sell
40,252
-47,249
-54% -$764K 0.54% 44
2022
Q4 		$2.03M Buy
87,501
+6,794
+8% +$157K 1.54% 17
2022
Q3 		$1.79M Buy
80,707
+31,483
+64% +$750K 2.28% 15
2022
Q2 		$948K Buy
+49,224
New +$1.1M 1.07% 24

Other funds holding LENZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Privium Fund Management (UK)'s LENZ Position: Q4 2023 in Review

Privium Fund Management (UK) sold out of LENZ Therapeutics (LENZ) in Q4 2023, closing a stake of 27,321 shares — an estimated $453K sold.

Privium Fund Management (UK) first reported a position in LENZ in Q2 2022 and held it in 6 quarters. The position peaked at $2.03M in Q4 2022. 63 funds tracked by Wall St. Rank hold LENZ as of Q4 2023.

  • Privium Fund Management (UK) reported no remaining LENZ Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Privium Fund Management (UK) sold 27,321 LENZ Therapeutics shares in Q4 2023, an estimated $453K.
  • Privium Fund Management (UK) first reported a position in LENZ Therapeutics in Q2 2022 and held it in 6 quarters.
  • Privium Fund Management (UK)'s LENZ Therapeutics position peaked at $2.03M in Q4 2022.
  • 63 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2023.

Based on Privium Fund Management (UK)'s 13F filing for Q4 2023, filed 13 Feb 2024.